力平脂治疗原发性高脂血症的近期疗效分析

Clinical Observation on Primary Hyperlipidemia Treated with Lypantyl

本文观察了５６例原发性高脂血症患者服用力平脂（ＬｙＰａｎｔｙｌ）３００ｍｇ／ｄ，４周后的血脂变化，并与接受诺衡（Ｇｅｍｆｉｂｒｏｂｉｌ）１２００ｍｇ／ｄ，治疗的９７例相同条件患者作了比较。提示两药的调脂作用相似，但力平脂的降血胆固醇、甘油三脂作用较诺衡显著，统计学上有显著差异（Ｐ＜０．０５）；但降低血胆固醇与高密度脂蛋白胆固醇比值方面两者相似；力平脂副反应发生率显著低于诺衡组（Ｐ＜０．０００１）。结果表明，两药均适用于甘油三脂升高及高密度脂蛋白胆固醇降低为主的患者，尤以力平脂为优。

The authors observed the blood fat changes of 56 cases of which the patients suffered from primary hyperlipidemia and had taken Lypantyl for four weeks (300mg/day).They also compared these cases with other 97cases in which Gemfibrozil had been taken for treatment of the patients under the similiar conditions. As a result, the authors found the two medicines had the similar effects in the adjustment of blood fat. However,Lypantyl had more remarkable effects than Gemfibrozil did in the reduction of cholesterolemia and triglyceride(P <0. 05). There remained a similiar rate in the reduction of TC/HDL ─ C, and furthermore, Lypantyl had a lower incidency rate of deleterious reaction than Gemfibrozil did (P <0. 0001). The observations proved that the two medicines could both be applied for the patients with a higher TG and lower HDL─C, but Lypantyl was the preferable choice.